Description
BioS-1P is a synthetic analogue of the human glucagon-like peptide-1 (GLP-1), engineered for a prolonged half-life, allowing for less frequent administration. As a selective GLP-1 receptor agonist, its primary mechanism of action involves mimicking the endogenous incretin hormone, which plays a crucial role in glucose homeostasis. Semaglutide stimulates insulin secretion from pancreatic β-cells and suppresses glucagon release from α-cells in a glucose-dependent manner. This dual action helps to regulate blood glucose levels effectively. Additionally, it delays gastric emptying, which contributes to a reduction in postprandial glucose excursions and promotes a feeling of satiety.
Key areas of research for Semaglutide have predominantly focused on its potent anti-diabetic effects in the management of type 2 diabetes. Its therapeutic potential extends to weight management, where it has demonstrated significant efficacy in promoting weight loss by reducing appetite and caloric intake. Furthermore, ongoing studies are exploring its cardiovascular benefits, including the mitigation of atherosclerotic progression, and its potential neuroprotective properties.
This product is intended for laboratory research use only and is not for human or veterinary use.
CAS: 910463-68-2
PubChem CID: 56843331
Molecular Formula: C187H291N45O59
Molecular Weight: 4113.64 g/mol
Amino Acid Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-C18 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Physical Form: Lyophilized Powder
Purity: ≥99%
Storage: -20°C, protected from light and moisture
